Stella Pharma Income Statement

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Revenue	968	961	269	229	100	205
Revenue Growth (YoY)	199.69%	257.25%	17.47%	129.00%	-51.22%	-
Cost of Revenue	118	116	52	22	15	24
Gross Profit	850	845	217	207	85	181
Selling, General & Admin	733	590	571	625	555	539
Research & Development	328	328	393	374	255	307
Operating Expenses	1,078	935	977	1,013	826	862
Operating Income	-228	-90	-760	-806	-741	-681
Interest Expense	-6	-4	-2	-2	-3	-3
Interest & Investment Income	1	1	1	1	-	-
Other Non Operating Income (Expenses)	-44	-45	-	31	-20	27
Pretax Income	-277	-138	-761	-776	-764	-657
Income Tax Expense	2	2	2	2	3	2
Net Income	-279	-140	-763	-778	-767	-659
Net Income to Common	-279	-140	-763	-778	-767	-659
Shares Outstanding (Basic)	34	33	31	29	28	20
Shares Outstanding (Diluted)	34	33	31	29	28	20
Shares Change (YoY)	4.11%	7.76%	7.27%	2.83%	40.17%	28.43%
EPS (Basic)	-8.20	-4.19	-24.63	-26.94	-27.31	-32.89
EPS (Diluted)	-8.20	-4.19	-24.63	-26.94	-27.31	-32.89
Free Cash Flow	-	136	-886	-853	-1,127	-793
Free Cash Flow Per Share	-	4.07	-28.60	-29.54	-40.13	-39.58
Gross Margin	87.81%	87.93%	80.67%	90.39%	85.00%	88.29%
Operating Margin	-23.55%	-9.37%	-282.53%	-351.96%	-741.00%	-332.19%
Profit Margin	-28.82%	-14.57%	-283.64%	-339.74%	-767.00%	-321.46%
Free Cash Flow Margin	-	14.15%	-329.37%	-372.49%	-1127.00%	-386.83%
EBITDA	-194.75	-56	-725	-771	-707	-650
EBITDA Margin	-20.12%	-5.83%	-269.52%	-	-	-
D&A For EBITDA	33.25	34	35	35	34	31
EBIT	-228	-90	-760	-806	-741	-681
EBIT Margin	-23.55%	-9.37%	-282.53%	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.